Riskpilot← Back to searchSign inGet full accessBengt Lavö AB
ABActiveOrg 5566564513Boo Strandväg 1 CMedical specialists activities · NACE 8622Est. 20041 employees
Revenue 2025
SEK 1,2M
+37% vs 2024
EBITDA margin
66.0%
+4% vs 2024
Equity ratio
71.3%
Financial strength
Net profit 2025
SEK 758K
+77% vs 2024
| Revenue | SEK 1,2M | +37% |
| EBITDA | SEK 763K | +4% |
| Net profit | SEK 758K | +77% |
| Total assets | SEK 6,9M | +17% |
| Equity | SEK 4,9M | +13% |
| Employees | 1 | — |
Legal name
Bengt Lavö AB
Org number
5566564513
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
23 februari 2004
Share capital
SEK 400 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva medicinsk verksamhet med inriktning på mag- och tarmsjukdomar samt därmed förenlig verksamhet.
Address
Boo Strandväg 1 C
Phone
+4684417455
Email
bengt.lavo@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 207 | 700 | 727 | 844 | 1 156 |
| Staff expenses | — | — | — | — | −289 |
| EBITDA | −15 | 580 | 543 | 737 | 763 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −112 |
| EBIT | −15 | 580 | 543 | 737 | 651 |
| Net financials | — | — | 1 | 3 | 368 |
| Profit before tax | −15 | 580 | 544 | 541 | 859 |
| Tax | −0 | −98 | −113 | −112 | −102 |
| Net profit | −15 | 482 | 431 | 429 | 758 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 973 | 5 088 | 5 378 | 5 883 | 6 857 |
| Equity | 3 549 | 3 850 | 4 101 | 4 330 | 4 888 |
| Long-term debt | 602 | 0 | 0 | 0 | — |
| Short-term debt | 822 | 1 237 | 1 276 | 1 553 | 1 809 |
| Total debt | 1 424 | 1 237 | 1 276 | 1 553 | 1 809 |
EBITDA margin
66.0%
This company
15.8%
Market median
+318% vs market
20212025
Equity ratio
71.3%
This company
38.2%
Market median
+87% vs market
20212025
Return on equity
15.5%
This company
18.4%
Market median
+16% vs market
20212025
Net profit margin
65.6%
This company
8.1%
Market median
+710% vs market
20212025
Asset turnover
0.17×
This company
1.12×
Market median
-85% vs market
20212025
Debt / equity
0.40×
This company
0.62×
Market median
+35% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LG | Audit | 2022 |
PH Auditor Substitute | Auditor Substitute | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bengt Lavö AB 
Bengt Lavö Medicinsk Konsult ABBoard members of Bengt Lavö AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leif Gustav Rantatalo | Audit | 0 companies |
| Per Hjalmar Lindblom | Auditor Substitute | 0 companies |
| Anna V H Guldevall Lavö | Deputy Board Member | 0 companies |
| Carl Gunnar Vilhelm Lavö | Board of Directors | 0 companies |
| Bengt Johan Vilhelm Lavö | Chairman | 0 companies |